ATP binding cassette subfamily A member 5Genealiases: ABC13 · DEL17q24 · EST90625 · HTC3 · HTGH
Q-omics provides the consensus-scored ABCA5 profile across patient tissues and cancer cell-line models. ABCA5 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, ABCA5 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, ABCA5 RNA expression shows 20,208 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight PAAD, COAD, and UVM as cancer lineages where ABCA5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ABCA5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ABCA5 survival associations across molecular data types. ABCA5 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (7) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ABCA5 RNA expression–survival associations across cancer types. High ABCA5 expression shows unfavorable associations in LGG, but favorable associations in PAAD, KIRC, BRCA, LUSC and COAD. The PAAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify PAAD as the clearest survival context for ABCA5 RNA expression.
This table summarizes ABCA5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 1. The strongest signals are observed in COAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for ABCA5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ABCA5 shows lower tumor expression in COAD, THCA, KIRP, READ, BRCA and HNSC. The COAD box plot shows higher ABCA5 RNA expression in normal versus tumor tissue (log2 FC = −1.325, t-test p < 0.001).
This table shows molecular features associated with ABCA5 in patient tissues and cancer cell lines. In patient samples, ABCA5 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ABCA5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and UPPER_AERODIGESTIVE_TRACT.
